Michael Burkes Brophy sold $7.8M of NTRA
CHIEF FINANCIAL OFFICER at Natera, Inc.. 43,902 shares at an average of $176.85, traded Jan 31, 2025, filed Feb 4, 2025.
Score components
- +22RoleCFO
- +25Trade size$7.8M at market
- +10Share of holdings soldSold 38% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-003079, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2025 | AGrant or award Common Stock10b5-1 | +12,720 | - | - | 114,531 | Feb 4, 2025 |
| Jan 31, 2025 | SOpen-market sale Common Stock10b5-1 | -400 | $173.05 | $69k | 114,131 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -3,500 | $175.39 | $614k | 110,631 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -17,140 | $176.61 | $3.0M | 93,491 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -21,362 | $177.25 | $3.8M | 72,129 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $178.19 | $267k | 70,629 | Feb 4, 2025 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 48Moderate | sell 210b5-1 | NTRA Natera, Inc. | Jonathan Sheena director, other | $7.0M | 18,064 | |
| 35Weak | sell 410b5-1 | NTRA Natera, Inc. | Jonathan Sheena director, other | $3.2M | 9,150 | |
| 40Moderate | sell 410b5-1 | NTRA Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M | 102,000 | |
| 40Moderate | sell 410b5-1 | NTRA Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M | 50,000 | |
| 39Weak | sell 410b5-1 | NTRA Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k | 1,698 | |
| 45Moderate | sell 410b5-1 | NTRA Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M | 18,160 | |
| 27Weak | sell 310b5-1 | NTRA Natera, Inc. | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | $116k | 792 | |
| 45Moderate | sell 310b5-1 | NTRA Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $979k | 6,702 | |
| 25Weak | sell 310b5-1 | NTRA Natera, Inc. | John Fesko PRESIDENT, CHIEF BUS. OFFICER | $116k | 795 | |
| 55Moderate | sell 310b5-1 | NTRA Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $13M | 87,272 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.